BIOMAT Database Logo BIOMAT Database Logo

Clinical evaluation of a new anthracycline antibiotic, aclacinomycin-A, in patients with advanced malignant lymphoma. 1983

R P Warrell, and S J Kempin

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009279 Naphthacenes Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES. Tetracenes,Benz(b)Anthracenes
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D015250 Aclarubicin An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity. Aclacinomycin A,Aclacin,Aclaplastin,MA-144A1,NSC-208734,MA 144A1,MA144A1,NSC 208734,NSC208734

Related Publications

R P Warrell, and S J Kempin
Aclacinomycin ZIMET 33352--a new anthracycline antibiotic.
January 1989, Journal of basic microbiology,
R P Warrell, and S J Kempin
New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials.
January 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
R P Warrell, and S J Kempin
Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A.
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
R P Warrell, and S J Kempin
Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
January 1986, Drugs under experimental and clinical research,
R P Warrell, and S J Kempin
Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.
October 1983, Cancer treatment reports,
R P Warrell, and S J Kempin
[Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
December 1985, Antibiotiki i meditsinskaia biotekhnologiia = Antibiotics and medical biotechnology,
R P Warrell, and S J Kempin
Production of new anthracycline antibiotic betaclamycin B by microbial conversion with a specific aclacinomycin-negative mutant.
June 1992, The Journal of antibiotics,
R P Warrell, and S J Kempin
[Aclacinomycin A: a new antitumor antibiotic].
January 1982, Antibiotiki,
R P Warrell, and S J Kempin
Aclacinomycin X, a novel anthracycline antibiotic produced by Streptomyces galilaeus ATCC 31133.
May 1996, Bioscience, biotechnology, and biochemistry,
R P Warrell, and S J Kempin
Combination chemotherapy with a new anthracycline glycoside, aclacinomycin-A, and active drugs for malignant lymphomas in P388 mouse leukemia system.
August 1979, Gan,
Copied contents to your clipboard!